Moleculin reports pooled analysis shows no cardiotoxicity signal for Annamycin in five trials
Bitget2026/09/28 11:01- Moleculin Biotech reported peer-reviewed results from a pooled analysis of five Annamycin trials published in Frontiers in Cardiovascular Medicine.
- Findings were previously presented in clinical updates, now reinforced by journal publication and an independent Cleveland Clinic cardio-oncology review.
- The analysis found no signs of treatment-related heart damage, supporting Annamycin’s positioning as a potentially safer anthracycline.
- Data came from 90 patients in AML or metastatic soft tissue sarcoma, supporting continued development in the MIRACLE program for relapsed or refractory AML.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CNN Enters Generative AI Partnership with Google
US Stock Market Movement | Nvidia-backed AI pharmaceutical company Iambic Therapeutics (IAM.US) debuts on Nasdaq, surging over 11% after opening
As of press time, the stock is up more than 11%, trading at $17.77.
US Stock Market Movement | 3D Printing Materials Supplier Amaero (AMRO.US) Debuts on US Stock Market, Trading Halt Triggered After Opening
Amaero, a manufacturer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has gone public on the US stock market.
Crypto prices
More
